MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
*Driving Forces: Market Research, Intelligence, Analysis, Datapoints, Databases & Trends
2023: Top 20 Genomics Companies in the World
Blueprint Medicines Corporation (NASDAQ: BPMC)
Organization & Developments: Blueprint
Parents
Blueprint Medicines Corporation (NASDAQ: BPMC)
Children
*Develops cancer therapies that harness the growing understanding of the molecular blueprint of cancer
*Focus is on developing “personalized” cancer treatments based on molecular and cancer genome data and a proprietary chemical-compound library
2017: Blueprint Medicines: Buy The Secondary - Blueprint Medicines (NASDAQ:BPMC)
2017: Blueprint: The Uptrend Continues In 2017 - Blueprint Medicines (NASDAQ:BPMC)
2019: Blueprint Medicines: GIST Setback Unlikely To Deter Futureseekingalpha.com
2020: After a PhIII failure, the FDA delivers Blueprint an expected CRL – Endpoints News
2020: Blueprint Medicine's Most Recent Raise Is A Necessary Desperation_seekingalpha.com
2020: CORRECTED-BRIEF-Blueprint Medicines Receives FDA Approval For Ayvakit For Treatment Of Rare Stomach Cancer
2021: Blueprint's Avapritinib In Systemic Mastocytosis: A Comparative Analysis
2021: Rare Blood Disease Drug Win Marks Fourth Approval for Blueprint Medicines
2022: Blueprint Medicines: A Slow But Steady Blueprint For Succes_ seekingalpha.com
2023: Blueprint Medicines' Ayvakit: Capturing The ISM Niche (Rating Upgrade)
2024; Blueprint Medicines' SWOT analysis: stock soars on Ayvakit success, pipeline potential
2024: Blood Cancer-Focused Blueprint Medicines Could Be 'Attractive Target For Partnerships': Analyst
2024: Blueprint Medicines to Present the First Promising and Most Advanced Clinical Data for a CDK2 Inhibitor in Combination with an Approved CDK4/6 Inhibitor in HR+/HER2- Breast Cancer at the 2024 ASCO Annual Meeting
2024: Blueprint Medicines: Ayvakit Revenue Surge Fuels Optimism (Rating Upgrade)
2024: Blueprint Medicines: Growth For The Long Term Still Mostly Priced In_seekingalpha.com
2024: Blueprint Medicines: Looking Toppy_ seekingalpha.com
2024: Blueprint Medicines' Growth With AYVAKIT And Next-Gen Oncology Drugs _ seekingalpha.com
2024: Blueprint's mastocytosis drug Ayvakit cleared for NHS use
2025: Sanofi to buy US biopharma group Blueprint for up to $9.5 billion
Jumps
*Key People: Blueprint
Finance & Acquisitions: Blueprint